4-溴-6-甲氧基-1(2H)-异喹啉酮 | 923278-23-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异喹啉及其衍生物
• 中文名称: 4-溴-6-甲氧基-1(2H)-异喹啉酮
• 英文名称: 4-bromo-6-methoxyisoquinolin-1(2H)-one
• 英文别名: 4-bromo-6-methoxy-2H-isoquinolin-1-one
• CAS: 923278-23-3
• 化学式: C₁₀H₈BrNO₂
• 分子量: 254.083
• InChiKey: SXBLACDTTLNQHX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-溴-6-甲氧基-1(2H)-异喹啉酮 在 sodium hydroxide 、 sodium sulfite 作用下， 以 四氢呋喃 、 水 、 乙酸乙酯 、 三氯氧磷 为溶剂， 生成 1-chloro-6-methoxyisoquinolin-4-ol
  参考文献：
  名称：

  Hepatitis C Virus Inhibitors

  摘要：

  丙型肝炎病毒抑制剂具有通式（I）如下。还公开了包含这些化合物的组合物以及使用这些化合物抑制HCV的方法。

  公开号：

  US20130115190A1
• 作为产物：
  描述：

  6-甲氧基异喹啉 在 N-溴代丁二酰亚胺(NBS) 、 sodium acetate 、 间氯过氧苯甲酸 、 bromo-tris(1-pyrrolidinyl)phosphonium hexafluorophosphate 作用下， 以 二氯甲烷 、 水 、 1,2-二氯乙烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 56.0h， 生成 4-溴-6-甲氧基-1(2H)-异喹啉酮
  参考文献：
  名称：

  WO2020123674A5

  摘要：

  公开号：

  WO2020123674A5

文献信息

• Hepatitis C virus inhibitors
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US09527885B2

  公开（公告）日：2016-12-27

  Hepatitis C virus inhibitors having the general formula (I) are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

  揭示了具有一般式（I）的丙型肝炎病毒抑制剂。还公开了包含这些化合物的组合物以及使用这些化合物抑制HCV的方法。
• HEPATITIS C VIRUS INHIBITORS
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20150376233A1

  公开（公告）日：2015-12-31

  Hepatitis C virus inhibitors having the general formula (I) are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

  揭示了具有一般式（I）的丙型肝炎病毒抑制剂。还公开了包含这些化合物的组合物和使用这些化合物抑制HCV的方法。
• MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS
  申请人：Simmen Kenneth Alan

  公开号：US20090281141A1

  公开（公告）日：2009-11-12

  Inhibitors of HCV replication of formula (I) and the N-oxides, salts, and stereoisomers thereof, wherein X is N, CH and where X bears a double bond it is C; R 1 is —OR 1 , —NH—SO 2 R 6 ; R 2 is hydrogen, and where X is C or CH, R 2 may also be C 1-6 alkyl; R 3 is hydrogen, C 1-6 alkyl, C 1-6 alkoxyC 1-6 alkyl, or C 3-7 cycloalkyl; R 4 is isoquinolinyl optionally substituted with one, two or three substituents each independently selected from C 1-6 alkyl, C 1-6 alkoxy, hydroxy, halo, polyhaloC 1-6 alkyl, polyhaloC 1-6 alkoxy, amino, mono- or diC 1-6 alkylamino, mono- or diC 1-6 alkylaminocarbonyl, C 1-6 alkylcarbonyl-amino, aryl, and Het; n is 3, 4, 5, or 6; each dashed line (represented by - - - - - ) represents an optional double bond; R 5 is hydrogen; aryl; Het; C 3-7 cycloalkyl optionally substituted with C 1-6 alkyl; or C 1-6 alkyl optionally substituted with C 3-7 cycloalkyl, aryl or with Het; R 6 is aryl; Het; C 3-7 cycloalkyl optionally substituted with C 1-6 alkyl; or C 1-6 alkyl optionally substituted with C 3-7 cycloalkyl, aryl or with Het; each aryl is phenyl optionally substituted with one, two or three substituents; and each Het is a 5 or 6 membered saturated, partially unsaturated or completely unsaturated heterocyclic ring containing 1 to 4 heteroatoms each independently selected from nitrogen, oxygen and sulfur, and being optionally substituted with one, two or three substituents; pharmaceutical compositions containing compounds (I) and processes for preparing compounds (I). Bioavailable combinations of the inhibitors of HCV of formula (I) with ritonavir are also provided.

  公式（I）及其N-氧化物，盐和立体异构体抑制HCV复制的抑制剂，其中X为N，CH，且X带有双键时为C; R1为—OR1，—NH—SO2R6; R2为氢，且当X为C或CH时，R2也可以是C1-6烷基; R3为氢，C1-6烷基，C1-6烷氧基C1-6烷基或C3-7环烷基; R4为异喹啉基，可选择地取代有一、两或三个取代基，每个取代基独立地选自C1-6烷基，C1-6烷氧基，羟基，卤素，多卤代C1-6烷基，多卤代C1-6烷氧基，氨基，一级或二级C1-6烷基氨基，一级或二级C1-6烷基氨基甲酰基，C1-6烷基甲酰氨基，芳基和Het; n为3、4、5或6;每个虚线（用- - - - -表示）表示可选的双键; R5为氢; 芳基; Het; C3-7环烷基，可选择地取代C1-6烷基; 或C1-6烷基，可选择地取代C3-7环烷基，芳基或与Het取代; R6为芳基; Het; C3-7环烷基，可选择地取代C1-6烷基; 或C1-6烷基，可选择地取代C3-7环烷基，芳基或与Het取代; 每个芳基为苯基，可选择地取代有一、两或三个取代基; 每个Het为含有1到4个杂原子的5或6元饱和，部分不饱和或完全不饱和的杂环，每个杂原子独立地选自氮，氧和硫，并可选择地取代有一、两或三个取代基; 包含化合物（I）的制药组合物以及制备化合物（I）的过程。还提供了公式（I）的抑制剂与利托那韦的生物利用度组合。
• MACROCYLIC INHIBITORS OF HEPATITIS C VIRUS
  申请人：Simmen Kenneth Alan

  公开号：US20100120855A1

  公开（公告）日：2010-05-13

  Inhibitors of HCV replication of formula (I), the N-oxides, salts, and stereochemically isomeric forms thereof, wherein each dashed line (represented by represents an optional double bond; X is N, CH and where X bears a double bond it is C; R 1 is aryl or a saturated, a partially unsaturated or completely unsaturated 5 or 6 membered monocyclic or 9 to 12 membered bicyclic heterocyclic ring system wherein said ring system contains one nitrogen, and optionally one to three additional heteroatoms selected from the group consisting of oxygen, sulfur and nitrogen, and wherein the remaining ring members are carbon atoms; wherein said ring system may be optionally substituted on any carbon or nitrogen ring atom with one, two, three, or four substituents; L is a direct bond, —O—, —O—C 1-4 alkanediyl-, —O—C(═O)—, —O—C(═O)—NR 4a — or —O—C(═O)—NR 4a C 1-4 alkanediyl-; R 2 is hydrogen, —OR 5 , —C(O)OR 5 , —C(═O)R 6 , —C(═O)NR 4a R 4b , —C(═O)NHR 4c , —NR 4a R 4b , —NHR 4c , —NR 4a SO p NR 4a R 4b , —NR 4a SO p R 7 , or B(OR 5 ) 2 ; R 3 is hydrogen, and where X is C or CH, R 3 may also be C 1-6 alkyl; n is 3, 4, 5, or 6; p is 1 or 2; aryl is phenyl, naphthyl, indanyl, or 1,2,3,4-tetrahydronaphthyl, each of which may be optionally substituted with one, two or three substituents; Het is a 5 or 6 membered saturated, partially unsaturated or completely unsaturated heterocyclic ring containing 1 to 4 heteroatoms each independently selected from nitrogen, oxygen and sulfur, being optionally condensed with a benzene ring, and wherein the group Het as a whole may be optionally substituted with one, two or three substituents; pharmaceutical compositions containing compounds (I) and processes for preparing compounds (I). Bioavailable combinations of the inhibitors of HCV of formula (I) with ritonavir are also provided.

  公式（I）的HCV复制抑制剂，其中N-氧化物，盐和立体化学异构体，其中每个虚线（由表示，表示可选的双键; X是N，CH，其中X带有双键，则为C; R1是芳基或饱和，部分不饱和或完全不饱和的5个或6个成员的单环或9至12个成员的双环杂环环系，其中所述环系含有一个氮，并且可选地含有一个至三个选自氧，硫和氮的群组的其他杂原子，其中剩余的环成员是碳原子;其中所述环系可以在任何碳或氮环原子上选择一个，两个，三个或四个取代基; L是直接键，-O-，-O-C1-4烷二基，-O-C（=O）-，-O-C（=O）-NR4a-或-O-C（=O）-NR4aC1-4烷二基; R2是氢，-OR5，-C（O）OR5，-C（=O）R6，-C（=O）NR4aR4b，-C（=O）NHR4c，-NR4aR4b，-NHR4c，-NR4aSOpNR4aR4b，-NR4aSOpR7或B（OR5）2; R3是氢，其中X是C或CH时，R3也可以是C1-6烷基; n为3、4、5或6; p为1或2;芳基是苯基，萘基，茚基或1,2,3,4-四氢萘基，每个都可以选择性地用一个，两个或三个取代基取代; Het是一个5个或6个成员的饱和，部分不饱和或完全不饱和的杂环环，其中每个独立选择自氮，氧和硫的1至4个杂原子，可选择地与苯环缩合，并且整个Het基团可以选择性地用一个，两个或三个取代基取代;含有化合物（I）的制药组合物和制备化合物（I）的过程也提供。还提供了公式（I）的HCV抑制剂与利托那韦的生物利用度组合。
• Macrocyclic Inhibitors of Hepatitis C Virus
  申请人：Simmen Kenneth Alan

  公开号：US20110237621A1

  公开（公告）日：2011-09-29

  Inhibitors of HCV replication of formula (I) the N-oxides, salts, and stereochemically isomeric forms thereof, wherein each dashed line (represented by ) represents an optional double bond; X is N, CH and where X bears a double bond it is C; R 1 is aryl or a saturated, a partially unsaturated or completely unsaturated 5 or 6 membered monocyclic or 9 to 12 membered bicyclic heterocyclic ring system wherein said ring system contains one nitrogen, and optionally one to three additional heteroatoms selected from the group consisting of oxygen, sulfur and nitrogen, and wherein the remaining ring members are carbon atoms; wherein said ring system may be optionally substituted on any carbon or nitrogen ring atom with one, two, three, or four substituents; L is a direct bond, —O—, —O—C 1-4 alkanediyl-, —O—C(═O)—, —O—C(═O)—NR 4a — or —O—C(═O)—NR 4a C 1-4 alkanediyl-; R 2 is hydrogen, —OR 5 , —C(═O)OR 5 , —C(═O)R 6 , —C(═O)NR 4a R 4b , —C(═O)NHR 4c , —NR 4a R 4b , —NHR 4c , —NR 4a SO p NR 4a R 4b , —NR 4a SO p R 7 , or B(OR 5 ) 2 ; R 3 is hydrogen, and where X is C or CH, R 3 may also be C 1-6 alkyl; n is 3, 4, 5, or 6; p is 1 or 2; aryl is phenyl, naphthyl, indanyl, or 1,2,3,4-tetrahydronaphthyl, each of which may be optionally substituted with one, two or three substituents; Het is a 5 or 6 membered saturated, partially unsaturated or completely unsaturated heterocyclic ring containing 1 to 4 heteroatoms each independently selected from nitrogen, oxygen and sulfur, being optionally condensed with a benzene ring, and wherein the group Het as a whole may be optionally substituted with one, two or three substituents; pharmaceutical compositions containing compounds (I) and processes for preparing compounds (I). Bioavailable combinations of the inhibitors of HCV of formula (I) with ritonavir are also provided.

  公式（I）的HCV复制抑制剂包括其N-氧化物，盐和立体化学异构体，其中每个虚线（表示）代表可选的双键；X为N，CH，其中X带有双键时为C；R1为芳基或饱和的，部分不饱和的或完全不饱和的5或6个环成员的单环或9至12个环成员的双环杂环环系，其中所述环系含有一个氮，且可选地含有选自氧，硫和氮的一至三个附加杂原子，且所述剩余环成员为碳原子；其中所述环系可以在任何碳或氮环原子上可选地用一，二，三或四个取代基取代；L为直接键，—O—，—O—C1-4烷基二基，—O—C（═O）—，—O—C（═O）—NR4a—或—O—C（═O）—NR4aC1-4烷基二基；R2为氢，—OR5，—C（═O）OR5，—C（═O）R6，—C（═O）NR4aR4b，—C（═O）NHR4c，—NR4aR4b，—NHR4c，—NR4aSOpNR4aR4b，—NR4aSOpR7或B（OR5）2；R3为氢，且当X为C或CH时，R3也可以为C1-6烷基；n为3，4，5或6；p为1或2；芳基为苯基，萘基，茚基或1,2,3,4-四氢萘基，每个芳基可以选择地用一个，两个或三个取代基取代；Het为含有1至4个异原子的5或6个成员饱和的，部分不饱和的或完全不饱和的杂环环，每个异原子可独立地选自氮，氧和硫，可选择地与苯环融合，且作为整体的Het基团可以选择地用一个，两个或三个取代基取代；还提供了含有化合物（I）的制药组合物和制备化合物（I）的过程。公式（I）的HCV抑制剂与利托那韦的生物利用度组合也提供。